The United Kingdom has recorded its highest number of ketamine‑related deaths in a single year, with official figures showing 115 fatalities in 2025 – a dramatic rise from just seven a decade earlier and more than double the 60 deaths logged in 2024. The Office for National Statistics (ONS) data also reveals a 16‑fold increase in ketamine‑linked deaths across England and Wales since 2015, prompting renewed concern among health professionals about the drug’s escalating normalisation among young people. As the substance, originally developed as a veterinary anaesthetic, becomes cheaper than cocaine or MDMA, its presence at parties and social gatherings is increasingly common, despite the severe medical risks it carries, including irreversible bladder damage and, in the most extreme cases, death.
A stark statistical shift
The ONS release highlights a sharp upward trajectory: 27 ketamine‑related deaths were recorded in 2020, climbing to 60 in 2024 and peaking at 115 in 2025. The overall drug‑poisoning total fell slightly to 5,519 in 2025 from 5,565 the previous year, yet cocaine overtook heroin and morphine as the most frequently mentioned substance in fatal overdoses, with 1,233 cocaine‑linked deaths – equivalent to 20.7 per million population. The data underscores a broader trend of shifting preferences among users, with many turning to cheaper alternatives that are perceived as less dangerous.
Health impacts of chronic ketamine use
Regular consumption of ketamine can trigger a cascade of medical complications. In the short term, users may experience dissociation, intense hallucinations, nausea, agitation and a rapid heartbeat. Over months or years, the drug can inflict permanent damage to the bladder and urinary tract, often resulting in chronic pain that some individuals attempt to self‑medicate with further ketamine intake – a destructive feedback loop. Liver injury, severe weight loss leading to malnutrition and potential organ failure are also documented outcomes. Clinical services report that many patients present with advanced bladder scarring, requiring invasive treatments and long‑term monitoring.
Voices from the frontline
Lynne Weston, a clinical services manager at Turning Point, described the surge as “one of the cheapest substances to purchase, and it’s considered normal within many social settings as well.” She noted a notable shift in party culture: “We are seeing increased numbers of ketamine and the younger generation don’t tend to drink alcohol as much.” Admissions for ketamine addiction treatment in England have risen more than eightfold over the past ten years, she added. “In the short term, ketamine use can lead to dissociative behaviour and severe cardiovascular toxicity. You can have effects like hallucinations, nausea, agitation, and an increased heart rate,” Ms Weston explained. She also warned that re‑classifying the drug to Class A would likely deter people from seeking help, as criminalisation often increases stigma and fear of police involvement.
Dr James Morgan, a lecturer in addiction and mental health at London Metropolitan University, echoed concerns about the drug’s accessibility. “Deaths relating to ketamine have continued to increase, relating to lower prices, higher use and greater normalisation. Reports of young people experiencing dependency to ketamine and often acute health difficulties such as bladder damage are growing,” he said. Dr Morgan cautioned against a simple re‑classification, pointing out that “higher classifications have never been shown to reduce usage, especially when dealers already supply Class A substances such as cocaine and MDMA.”
A personal testimony adds a human dimension to the statistics. “My ketamine addiction got me locked up in Japan – don’t make same mistakes as me,” said one former user, highlighting the far‑reaching consequences that extend beyond health, affecting travel, legal status and personal relationships.
Policy debate and expert consensus
Ketamine has been a Class B substance in the UK since 2014, making possession illegal. Calls have intensified for it to be upgraded to Class A, reflecting worries that its current status downplays its danger. However, many experts, including Ms Weston and Dr Morgan, argue that a stricter classification would be counterproductive. “Criminalisation doesn’t stop people using substances and we wouldn’t support a reclassification,” Ms Weston noted. She emphasised that fear of legal repercussions often prevents users from accessing treatment, increasing the risk of severe health outcomes.
The broader drug‑related landscape shows mixed trends. While overall drug‑poisoning deaths edged down, the shift toward cocaine indicates that users are substituting one cheap, potent drug for another. This fluidity in preferences suggests that any policy response must address underlying socio‑economic factors, such as affordability and accessibility, rather than relying solely on legal categorisation.
Why it Matters
The surge in ketamine‑related fatalities signals a deepening public‑health emergency that transcends mere numbers. As the drug becomes entrenched in youth culture due to its low cost and growing social acceptance, the medical system faces mounting pressure to provide timely, non‑judgmental treatment and harm‑reduction services. Failure to act promptly risks entrenching a cycle of dependency, chronic illness and premature loss, while also exposing gaps in current drug‑policy approaches that may inadvertently discourage vulnerable individuals from seeking help. Addressing this crisis demands coordinated action: expanded access to addiction services, targeted education campaigns, and policies that prioritise health over punishment.
